瑞桑基祖马布在患有牛皮的HIV患者中的有效性和安全性:一系列病例
Diego Orsini1, Fabio S Maramao2, Luigi Gargiulo3,4
1Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
International journal of STD & AIDS
|September 11, 2023
概括
瑞桑基祖马布有效地清除了艾滋病毒感染者的牛皮. 这种生物疗法显示出强大的安全性,为这一群体提供了新的治疗选择.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 艾滋病毒/艾滋病研究研究
- 药理学 药理学 是一个学科.
背景情况:
- 生物疗法是严重斑块性牛皮的标准.
- 有限的数据存在于艾滋病毒患者的生物使用.
- 在艾滋病毒感染者中,牛皮往往没有得到充分的治疗.
研究的目的:
- 评估Risankizumab在艾滋病毒和斑块性牛皮患者的安全性和有效性.
- 为了解决有关该人群中双白素-23抑制剂的数据缺口.
主要方法:
- 四名艾滋病毒患者和中度至重度斑块性牛皮的病例系列.
- 用瑞桑基祖马布 (risankizumab) 治疗,瑞桑基祖马布是一种选择性互白素-23抑制剂.
- 在16周评估皮肤清除和不良事件.
主要成果:
- 四个患者都实现了完全或近乎完全的皮肤清除.
- 在16周的治疗期间,没有报告任何不良事件.
- 瑞桑基祖马布显示出显著的疗效和有利的安全性.
结论:
- 瑞桑基祖马布是艾滋病毒感染患者斑块性牛皮的安全有效治疗方法.
- 这个案例系列支持在这个代表性不足的人群中使用risankizumab.
- 需要进一步的研究,以在更大的研究中证实这些发现.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
147
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168


